GSK-3 is a viable potential target for therapeutic intervention in bipolar disorder
- 1 January 2007
- journal article
- review article
- Published by Elsevier BV in Neuroscience & Biobehavioral Reviews
- Vol. 31 (6), 920-931
- https://doi.org/10.1016/j.neubiorev.2007.03.002
Abstract
No abstract availableThis publication has 118 references indexed in Scilit:
- GLYCOGEN SYNTHASE KINASE 3β AS A TARGET FOR THE THERAPY OF SHOCK AND INFLAMMATIONShock, 2007
- The paradoxical pro- and anti-apoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathwaysProgress in Neurobiology, 2006
- A Positive Feedback Loop between Glycogen Synthase Kinase 3β and Protein Phosphatase 1 after Stimulation of NR2B NMDA Receptors in Forebrain NeuronsJournal of Biological Chemistry, 2005
- Lifetime Prevalence and Age-of-Onset Distributions of DSM-IV Disorders in the National Comorbidity Survey ReplicationArchives of General Psychiatry, 2005
- GSK-3 activity in neocortical cells is inhibited by lithium but not carbamazepine or valproic acidBipolar Disorders, 2005
- Effects of Valproic Acid Derivatives on Inositol Trisphosphate Depletion, Teratogenicity, Glycogen Synthase Kinase-3β Inhibition, and Viral Replication: A Screening Approach for New Bipolar Disorder Drugs Derived from the Valproic Acid Core StructureMolecular Pharmacology, 2005
- Lithium Inhibits Glycogen Synthase Kinase-3 by Competition for MagnesiumBiochemical and Biophysical Research Communications, 2001
- A GSK3‐binding peptide from FRAT1 selectively inhibits the GSK3‐catalysed phosphorylation of Axin and β‐cateninFEBS Letters, 1999
- The Croonian Lecture 1998. Identification of a protein kinase cascade of major importance in insulin signal transductionPhilosophical Transactions Of The Royal Society B-Biological Sciences, 1999
- Lithium inhibits glycogen synthase kinase-3 activity and mimics Wingless signalling in intact cellsCurrent Biology, 1996